Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adrian Richter has a total of 100 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Crystal structure of the meso compound (2 R ,6 S )-4-(5-bromopyrimidin-2-yl)-2,6-dimethylmorpholine

    by Paul R. Palme, Richard Goddard, Markus Leutzsch, Adrian Richter, Peter Imming, Rüdiger W. Seidel

    The title compound, C 10 H 14 N 3 OBr, was prepared by a nucleophilic aromatic substitution reaction between 2,6-dimethylmorpholine and 2-chloropyrimidine, followed by bromination of the pyrimidine ring. The compound crystallizes in the monoclinic system (space group P 2 1 /c) with four molecules in the unit cell ( Z = 4). The molecule exhibits approximate C S point-group symmetry (r.m.s. deviation: 0.1072 Å). The arrangement of the molecules in the solid state is dominated by close packing. C—H...N contacts between pyrimidinyl rings in adjacent molecules with an R 2 2 (6) motif are encountered, whereas the bromine atom does not exhibit any short contacts that could be regarded as halogen bonds.

  • Open Access

    Cytochrome P450-Mediated Metabolism of Antimycobacterial N α-Aroyl- N -aryl-phenylalanine Amides

    by Johannes Doering, Erik Meerz, Rüdiger W. Seidel, Markus Lang, Andreas M. Kany, Seppo Auriola, Risto Olavi Juvonen, Hannu Raunio, Richard Goddard, Matthew D. Zimmerman, et al.

    Nα-Aroyl-N-aryl-phenylalanine amides (AAPs) are a class of antimycobacterial substances that inhibit the RNA polymerase and are effective against various pathogenic and opportunistic mycobacteria, including Mycobacterium tuberculosis, Mycobacterium abscessus, and Mycobacterium avium. Further development of these promising compounds, however, has been hindered by their low microsomal stability, leading to insufficient bioavailability. The present study investigates the mechanism by which microsomal enzymes metabolically degrade AAPs and identifies the resulting metabolites using LC-MS/MS. Rapid oxidation of the ortho-phenylenediamine structure, present in various substances in this class, plays a key role in this process. Additionally, we demonstrated in vitro and in vivo that cytochrome P450 enzyme inhibitors significantly slow the degradation of AAPs. Identification of metabolites will inform further chemical modification of AAPs to achieve metabolic stability.

  • Open Access

    4-[4-(4-Chloro-1,2,5-thiadiazol-3-yl)phenyl]morpholine

    by Paul R. Palme, Richard Goddard, Adrian Richter, Peter Imming, Rüdiger W. Seidel

    The title compound, C 12 H 12 ClN 3 OS, was prepared using a Suzuki–Miyaura cross-coupling reaction. The compound was found to crystallize in the orthorhombic system (space group Pbca , Z = 8). The crystal structure was refined with non-spherical atomic form factors using Hirshfeld atom refinement. The mean planes through the thiadiazole ring and the benzene ring are inclined at an angle of 36.83 (2)°. The morpholine ring adopts a chair conformation with a markedly pyramidal bonding situation at the N atom. The crystal packing is dense, with a packing index of 75%.

  • Open Access

    Nucleophilic substitution of a phthalimidyl group with morpholine in an N 1 -methyl-1,2,3-triazole: crystallographic evidence for migration of the methylene bridge

    by Paul R. Palme, Richard Goddard, Markus Leutzsch, Adrian Richter, Peter Imming, Rüdiger W. Seidel

    2-{[4-(4-Bromophenyl)-1 H -1,2,3-triazol-1-yl]methyl}phthalimide, C 17 H 11 BrN 4 O, was synthesized by click chemistry employing a copper-catalyzed azide–alkyne 1,3-dipolar cycloaddition. The molecule adopts an angular structure and was found to crystallize in the monoclinic system (space group P 2 1 / n , Z = 4). Reaction with morpholine in the presence of a base afforded 4-{[4-(4-bromophenyl)-2 H -1,2,3-triazol-2-yl]methyl}morpholine, C 13 H 15 BrN 4 O, as the major product, involving a nucleophilic substitution of morpholine for the phthalimide group and migration of the substituent from N1 to N2 on the 1,2,3-triazole ring. The morpholine-substituted compound likewise crystallizes in the monoclinic system (space group P 2 1 / c , Z = 4) with the molecule exhibiting an angular shape. Both crystal structures appear to be governed by close packing, with weak C—H...O and C—H...N hydrogen bonds as the prevailing intermolecular interactions.

  • Open Access

    Transcription co-inhibition alters drug resistance evolution and enhances Mycobacterium tuberculosis clearance from granulomas

    by Barbara Bosch, Vanisha Munsamy-Govender, Jansy Sarathy, Mirjana Lilic, Paul Dominic B. Olinares, Kathryn A. Eckartt, Pranav Nalam, Markus Lang, Marcell Simon, Adrian Richter, et al.

    Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis, remains the deadliest human pathogen. Treatment is hampered by drug resistance and the persistence of slow-growing or non-replicating populations. Rifampicin, a cornerstone of first-line therapy, inhibits transcription during promoter escape, but resistance mutations undermine efficacy and drive resistance spread. We revisited the transcription cycle as an antibacterial target by characterizing AAP-SO2, an RNA polymerase inhibitor with whole-cell activity against Mtb. AAP-SO2 slows the nucleotide addition cycle, disrupting elongation and termination. Rifampicin-resistant mutations impose fitness costs by perturbing the balance of these steps, creating exploitable weaknesses. Inhibition of transcription with AAP-SO2 reduced the evolution of rifampicin resistance and was especially effective against the most common resistant mutant. Combination treatment with rifampicin and AAP-SO2 synergistically killed non-replicating Mtb in an ex vivo rabbit granuloma model. These findings show that exploiting functional vulnerabilities of the transcription cycle can counter rifampicin resistance and improve clearance of recalcitrant Mtb populations.


  • Open Access

    Design, Synthesis, and Biological Evaluation of Mono- and Diamino-Substituted Squaramide Derivatives as Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthase

    by Paul R. Palme, Shipra Grover, Rana Abdelaziz, Lea Mann, Andreas M. Kany, Lina Ouologuem, Karin Bartel, Lindsay Sonnenkalb, Norbert Reiling, Anna K. H. Hirsch, et al.

    Amides of squaric acid are new drug candidates with activity against mycobacteria. Like the approved drug bedaquiline, these compounds achieve efficacy by inhibiting mycobacterial ATP synthase. However, squaramides have a different binding site than bedaquiline and possess the potential to inhibit bedaquiline-resistant strains. We developed an optimized synthesis for monoamino-substituted squaric acid analogues. Guided by an atomic model of a squaramide compound bound to its target, we synthesized 31 new monoamino/diamino-substituted squaric acid derivates. The efficacy of these compounds was determined in whole-cell assays against Mycobacterium tuberculosis and Mycobacterium avium. The molecular target was confirmed with measurement of inhibition of Mycobacterium smegmatis ATP synthase and by using M. tuberculosis strains that modulate the expression of ATP synthase. Compared to earlier squaramides, several analogues demonstrated micromolar activity against M. tuberculosis, improved microsomal stability in vitro, and reduced cytotoxicity. These properties contribute to the preclinical development of this class of compound.


  • Open Access

    A Simple In Vitro Method to Determine Bactericidal Activity Against Mycobacterium abscessus Under Hypoxic Conditions

    by Ruth Feilcke, Robert Eckenstaler, Markus Lang, Adrian Richter, Peter Imming

    Background/Objectives: Non-replicating persisters (NRPs) of Mycobacterium abscessus are a bacterial subpopulation that can survive in the host under unfavorable conditions, such as hypoxia or nutrient starvation. The eradication of these bacteria is difficult, which is one reason for the long treatment duration and treatment failure. The drug discovery process should therefore contain methods to screen activity against NRPs. Methods: A hypoxic environment is used to generate NRPs of M. abscessus that are termed low-oxygen persisters (LOPs). For this, an oxidation process is used to transition a replicating culture of M. abscessus distributed in microtiter plates within a sealable box into LOPs. Colony counting, automated object counting, bactericidal activity determination of known agents, and confocal laser scanning microscopy are used to study the obtained culture. Results: The obtained culture shows typical attributes of non-replicating cells, such as significantly reduced replication, the reversibility of the LOP state under aerobic conditions, delayed regrowth on solid medium, altered morphological patterns on a single-cell level, and phenotypical resistance against a variety of clinically relevant antimycobacterial compounds. The study reveals metronidazole and niclosamide as bactericidal against M. abscessus LOPs. These compounds can be used as LOP verification compounds within the described model. Conclusions: Our model is easily implemented and quickly identifies compounds that are inactive under hypoxic conditions. It can therefore accelerate the identification of clinically effective antimycobacterial drug substances, and can be a helpful tool during the drug development process.


  • Open Access

    Synthesis and Antimycobacterial Assays of Some New Ethambutol Analogs

    by Rana Abdelaziz, Mthandazo Dube, Lea Mann, Adrian Richter, Dina Robaa, Norbert Reiling, Mohammad Abdel-Halim, Peter Imming

    Ethambutol (EMB) is a first-line anti-tuberculosis drug that is also considered in treatment regimens for infections caused by non-tuberculous mycobacteria (NTM). EMB targets the arabinosyl transferases EmbCAB, which are important for the synthesis of cell wall constituents. To further explore and narrow down the structural variability of EMB, we synthesized three series of new EMB analogs. We tested their activity against Mycobacterium tuberculosis, Mycobacterium smegmatis, Mycobacterium abscessus and Mycobacterium intracellulare. Only analogs that very closely resembled EMB showed comparable antimycobacterial activity.


  • Open Access

    Polymorphism of an Nα-Aroyl-N-Aryl-Phenylalanine Amide: An X-ray and Electron Diffraction Study

    by Markus Lang, Richard Goddard, Michael Patzer, Uday S. Ganapathy, Thomas Dick, Adrian Richter, Rüdiger W. Seidel

    In view of the rise of drug-resistant tuberculosis and difficult-to-treat related diseases caused by non-tuberculous mycobacteria, there is an urgent need for antimycobacterial drug discovery. Nα-aroyl-N-aryl-phenylalanine amides (AAPs) have been identified as antimycobacterial agents and are subject to lead optimization. The aim of the present study is to evaluate the impact of N-aryl ortho cyano substitution in a lead compound on the crystal and molecular structure and its in vitro activity against Mycobacterium abscessus. The title AAP can be conveniently synthesized from N-Boc-protected d-phenylalanine in two amide coupling steps using a previously established racemization-free method. Two polymorphic forms in the solid-state are described, as discovered by X-ray and electron diffraction. The introduction of a cyano group in the ortho position of the AAP N-aryl ring, however, leads to loss of in vitro activity against M. abscessus subsp. abscessus.